Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters

Prostate Cancer and Prostatic Diseases volume 5, pages 316–325 (2002)Cite this article

Abstract

Adenoviral vector delivery of the Herpes simplex virus thymidine kinase (HSV-tk) gene in combination with the prodrug ganciclovir (GCV) has been tested in phase I clinical trials for prostate cancer and found to exhibit a satisfactory toxicity profile. We have developed additional adenoviral vectors with differing promoters to optimize the expression profile and in the present study evaluate the potential systemic toxicity of these vectors. Four recombinant adenoviral vectors that express the HSV-tk gene were generated using three different promoters: CMV (leftward orientation); RSV (both rightward and leftward orientation); and the mouse caveolin-1 (cav-1) promoter (leftward orientation). Efficacy was determined in vitro by cytotoxicity assays in a mouse prostate cancer cell line, RM-9, and in vivo by treating orthotopic tumors. Potential toxicity was evaluated from liver histology and apoptotic cell counts and enzyme levels in the serum following intravenous adenoviral vector injection. Although there were differences in HSV-tk expression at the protein level among the four vectors there were no significant differences in in-vitro cytotoxicity studies with GCV or in vivo in tumor growth suppression of an orthotopic mouse prostate cancer model in GCV treated mice. Intravenous delivery of high doses of all adenoviral vectors lead to abnormalities in liver function as measured by specific serum markers and histological evaluation of liver tissue and increased levels of apoptosis in the liver. These abnormalities were most prevalent with the vector containing the CMV promoter and the rightward oriented RSV promoter. They were least prevalent in the vector regulated by the cav-1 promoter. Upregulation of specific chemokines, MIP-2 and MIP-1β was correlated with apoptotic counts. Our results demonstrate that comprehensive toxicological analysis of adenoviral vectors provides internally consistent information that can differentiate vectors with comparable efficacy based on toxicity. In these studies vectors with the cav-1 promoter-driven and leftward RSV-driven HSV-tk gene demonstrated minimal toxicities with cytotoxic effectiveness comparable to more toxic vectors. Our studies further suggest that promoter selection can influence the toxic effects of an adenoviral gene therapy vector.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10

Similar content being viewed by others

References

  1. Thompson TC . In situ gene therapy for prostate cancer Oncol Res 1999 11: 1–8

    CAS  PubMed  Google Scholar 

  2. Shalev M et al. Gene therapy for prostate cancer Urology 2001 57: 8–16

    Article  CAS  Google Scholar 

  3. Eastham JA et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models Hum Gene Ther 1996 7: 515–523

    Article  CAS  Google Scholar 

  4. Hall SJ et al. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer Int J Cancer 1997 70: 183–187

    Article  CAS  Google Scholar 

  5. Hall SJ et al. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer Cancer Gene Ther 1999 6: 54–63

    Article  CAS  Google Scholar 

  6. Herman JR et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial Hum Gene Ther 1999 10: 1239–1249

    Article  CAS  Google Scholar 

  7. Shalev M et al. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer J Urol 2000 163: 1747–1750

    Article  CAS  Google Scholar 

  8. Miles BJ et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy Hum Gene Ther 2001 12: 1955–1967

    Article  CAS  Google Scholar 

  9. Ayala G et al. Cytopathic effects of in situ gene therapy in prostate cancer Hum Pathol 2000 31: 866–870

    Article  CAS  Google Scholar 

  10. Teh BS et al. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer—a preliminary report Int J Radiat Oncol Biol Phys 2001 51: 605–613

    Article  CAS  Google Scholar 

  11. Klatzmann D et al. A phase I/II dose-escalation study of herpes simples virus type 1 thymidine kinase “suicide” gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma Hum Gene Ther 1998 9: 2585–2594

    CAS  PubMed  Google Scholar 

  12. Klatzmann D et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma Hum Gene Ther 1998 9: 2595–2604

    CAS  PubMed  Google Scholar 

  13. Rodriguez R et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Cancer Res 1997 57: 2559–2563

    CAS  PubMed  Google Scholar 

  14. Freytag SO et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy Hum Gene Ther 1998 9: 1323–1333

    Article  CAS  Google Scholar 

  15. Hitt MM, Graham FL . Adenovirus vectors for human gene therapy Adv Virus Res 2000 55: 479–505

    Article  CAS  Google Scholar 

  16. Galanis E, Vile R, Russell SJ . Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors Crit Rev Oncol Hematol 2001 38: 177–292

    Article  CAS  Google Scholar 

  17. Muruve DA, Barnes MJ, Stillman IE, Libermann TA . Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo Hum Gene Ther 1999 10: 965–976

    Article  CAS  Google Scholar 

  18. van der Eb MM et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration Gene Ther 1998 5: 451–458

    Article  CAS  Google Scholar 

  19. Kaneko S et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression Cancer Res 1995 55: 5283–5287

    CAS  PubMed  Google Scholar 

  20. Wills KN et al. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene Cancer Gene Ther 1995 2: 191–197

    CAS  PubMed  Google Scholar 

  21. Brand K et al. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach Gene Ther 1998 5: 1363–1371

    Article  CAS  Google Scholar 

  22. Gotoh A et al. Development of human prostate cancer J Urol 1998 160: 220–229

    Article  CAS  Google Scholar 

  23. Koeneman KS et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis World J Urol 2000 18: 102–110

    Article  CAS  Google Scholar 

  24. Pramudji C et al. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter Clin Cancer Res 2001 7: 4272–4279

    CAS  PubMed  Google Scholar 

  25. Yang G et al. Elevated expression of caveolin is associated with prostate and breast cancer Cliin Cancer Res 1998 4: 1873–1880

    CAS  Google Scholar 

  26. Nasu Y et al. Suppression of caveolin expression induces oxygen androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. [See comments.] Nat Med 1998 14: 1062–1064

    Article  Google Scholar 

  27. Thompson TC, Southgate J, Kitchener G, Land H . Multistage carcinogenesis induced by ras and myc oncogenes ina reconstituted organ Cell 1989 56: 917–930

    Article  CAS  Google Scholar 

  28. Baley PA et al. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer J Steroid Biochem Mol Biol 1995 52: 403–413

    Article  CAS  Google Scholar 

  29. Gavrieli Y, Sherman Y, Ben-Sasson SA . Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation J Cell Biol 1992 119: 493–501

    Article  CAS  Google Scholar 

  30. Chen SH et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo Proc Natl Acad Sci USA 1994 91: 3054–3057

    Article  CAS  Google Scholar 

  31. Goodman JC et al. Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: pathologic, radiologic, and molecular studies Hum Gene Ther 1996 7: 1241–1250

    Article  CAS  Google Scholar 

  32. Timme TL et al. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice Cancer Gene Ther 1998 5: 74–82

    CAS  PubMed  Google Scholar 

  33. Nasu Y et al. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer Prostate Cancer Prostat Dis 2001 4: 44–55

    Article  CAS  Google Scholar 

  34. Trask TW et al. Phase I study of adenoviral delivery of the HSF-tk gene and ganciclovir administration in patients with current malignant brain tumors Mol Ther 2000 1: 195–203

    Article  CAS  Google Scholar 

  35. Timme TL et al. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis Oncogene 2000 19: 3256–3265

    Article  CAS  Google Scholar 

  36. Perricaudet LD, Makeh I, Perricaudet M, Briand P . Widespread long-term gene transfer to mouse skeletal muscles and heart J Clin Invest 1992 90: 626–630

    Article  Google Scholar 

  37. Wang J, Bucana C, Roth J, Zhang W . Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53 Cancer Gene Ther 1995 2: 9–17

    CAS  PubMed  Google Scholar 

  38. Nyberg-Hoffman C et al. Sensitivity and reproducibility in adenoviral infectious titer determination Nat Med 1997 3: 808–811

    Article  CAS  Google Scholar 

  39. Mittereder N, March KL, Trapnell BC . Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy J Virol 1996 70: 7498–7509

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Nasu Y et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model Gene Ther 1999 6: 338–349

    Article  CAS  Google Scholar 

  41. Serfling E, Jasin M, Schaffner W . Enhancers and eukaryotic gene transcription Trends Genet 1985 1: 224–230

    Article  CAS  Google Scholar 

  42. Addison CL, Hitt M, Kunsken D, Graham FL . Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors J Gen Virol 1997 78: 1653–1661

    Article  CAS  Google Scholar 

  43. Driesse MJ et al. Intracerebral injection of adenovirus harbouring the HSVtk gene combined with ganciclovir administration: toxicity study in nonhuman primates Gene Ther 1998 5: 1122–1129

    Article  CAS  Google Scholar 

  44. Lozier JN et al. Toxicity of a first-generation adenoviral vector in rhesus macaques Hum Gene Ther 2002 13: 113–124

    Article  CAS  Google Scholar 

  45. Morral N et al. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons Hum Gene Ther 2002 13: 143–154

    Article  CAS  Google Scholar 

  46. Borgland SL et al. Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsis-dependent activation of NF-kappaB J Virol 2000 74: 3941–3947

    Article  CAS  Google Scholar 

  47. Bowen GP et al. Adenovirus vector-induced inflammation: capsid-dependent induction of the C-C chemokine RANTES requires NF-kappaB Hum Gene Ther 2002 13: 367–379

    Article  CAS  Google Scholar 

  48. Zhang Y et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages Mol Ther 2001 3: 697–707

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by Specialized Program for Research Excellence (SPORE) grant from NCI (P50-58204) and the use of facilities at the Houston Veterans Affairs Medical Center.

Author information

Author notes

  1. E Aguilar-Cordova

    Present address: Harvard Gene Therapy Initiative, Harvard Medical School, Boston, MA

Authors and Affiliations

  1. Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA

    S Ebara, S Shimura, Y Nasu, G Yang, J Wang, T L Timme & T C Thompson

  2. Department of Urology, Okayama Medical School, Okayama, Japan

    S Ebara, Y Nasu, H Kaku & H Kumon

  3. Veteran's Affairs Medical Center, Houston, Texas, USA

    T L Timme & T C Thompson

  4. Gene Vector Laboratory, Baylor College of Medicine, Houston, Texas, USA

    E Aguilar-Cordova

  5. Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA

    T C Thompson

  6. Department of Radiotherapy, Baylor College of Medicine, Houston, Texas, USA

    T C Thompson

Authors
  1. S Ebara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Shimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Nasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Kaku
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Kumon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T L Timme
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Aguilar-Cordova
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T C Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T C Thompson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ebara, S., Shimura, S., Nasu, Y. et al. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters. Prostate Cancer Prostatic Dis 5, 316–325 (2002). https://doi.org/10.1038/sj.pcan.4500610

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500610

Keywords

This article is cited by

Search

Advanced search

Quick links